arginine has been researched along with arginine butyrate in 44 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 10 (22.73) | 18.7374 |
1990's | 17 (38.64) | 18.2507 |
2000's | 8 (18.18) | 29.6817 |
2010's | 9 (20.45) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cerutti, I; Chany, C; Pouillart, P; Ronco, G; Villa, P | 2 |
Cerutti, I; Pieri, F; Pouillart, P; Ronco, G; Trouvin, JH; Villa, P | 1 |
Cerutti, I; Chany, C | 5 |
Baillet, J; Brazier, M; Cerutti, I; Chany, C; Daniel, P; Desmet, G; Pieri, F; Tardivel, I | 1 |
Chany, C; Matsuguchi, M; Moreau, L; Rousset, S | 1 |
Chany, C; Raymond, J | 1 |
Pusztai, R; Taródi, B | 1 |
Cerutti, I; Chany, C; Mace, B | 1 |
Dover, GJ; Faller, DV; Ginder, GD; Olivieri, NF; Perrine, SP; Vichinsky, EP | 1 |
Collins, AF; Dover, GJ; Luban, NL | 1 |
Bunn, HF | 1 |
Cai, SP; Dover, GH; Faller, DV; Ginder, GD; Ikuta, T; Olivieri, NF; Perrine, SP; Vichinsky, EP; Witkowska, HE | 1 |
Faller, DV; Perrine, SP | 1 |
Dover, GJ; Ginder, GD; Little, J; Olivieri, NF; Sher, GD; Yang, S | 1 |
Lal, A; Marwaha, RK | 1 |
Olivieri, NF; Sher, GD | 1 |
Bubley, GJ; Emi, Y; Foss, F; Kupiec, N; O'Brien, M; Patierno, SR; Sanders, D; Teicher, BA; Xu, J | 1 |
Gromova, N; Lidaks, M; Maurinsh, Y; Poluektova, L | 1 |
Faller, DV; Fingeroth, J; Mentzer, SJ; Perrine, SP; Reilly, JJ | 1 |
Foss, FM; Koc, Y; Urbano, A | 1 |
Bolton, LL; Cackovic, M; Chung, C; Kerstein, MD | 1 |
Faller, DV; Forman, LW; Perrine, SP; Phelan, MW | 1 |
Faller, DV; Mentzer, SJ; Perrine, SP | 2 |
Foss, FM; Gorgun, G; Shao, RH; Tian, X; Urbano, AG | 1 |
Aron, A; McGovern, MM; Perrine, SP; Wasserstein, MP | 1 |
Atweh, GF; Galperin, Y; Ji, X; Li, Q; Liebhaber, SA; Perrine, S; Stamatoyannopoulos, G; Sutton, M; Weinberg, RS | 1 |
Brousse, N; Canioni, D; Damotte, D; Faller, DV; Ghez, D; Hermine, O; Lefrère, F; Perrine, SP; Varet, B | 1 |
Askin, M; Boulad, F; Di Nicola, M; Faller, DV; Fingeroth, J; Gianni, AM; Hermine, O; Horwitz, S; Klein, C; Levy, A; Mentzer, SJ; O'Reilly, R; Perrine, SP; Small, T; Suarez, F | 1 |
DiNardo, CD; Tsai, DE | 1 |
Becker, M; Bossi, L; Cha, HJ; de la Porte, S; Escolar, DM; Farajian, V; Francia, D; Gernapudi, R; Gordish-Dressman, H; Guerron, AD; Hoffman, EP; Nagaraju, K; Pandey, GS; Partridge, T; Pistilli, E; Rawat, R; Sali, A; Spurney, CF; Zerr, P | 1 |
Adams-Graves, P; Askin, M; Castaneda, SA; Eberhardt, RT; Faller, DV; McMahon, L; Perrine, SP; Sutton, M; Tamary, H; Wright, EC | 1 |
Chagneau, C; De La Porte, S; Laroche, S; Le Blanc, P; Mornet, D; Perronnet, C; Samson-Desvignes, N; Vaillend, C | 1 |
Knight-Madden, JM; Martí-Carvajal, AJ; Martinez-Zapata, MJ | 2 |
Bossi, L; de la Porte, S; Escolar, D; Fougerousse, F; Foutz, AS; Gillet, B; Haddad, H; He, X; Israël, M; Matecki, S; Perronnet, C; Roulot, M; Sebrié, C; Vaillend, C; Vianello, S; Voisin, V; Yu, H | 1 |
Benoit, E; Bich, C; Brunelle, A; Cancela, JM; Consolaro, F; de la Porte, S; Israël, M; Lanchec, E; Roulot, M; Touboul, D; Vianello, S | 1 |
Benoit, E; Boerio, D; Bouyon, S; de la Porte, S; Fromes, Y; Herbin, M; Roulot, M; Sebrié, C; Vianello, S | 1 |
6 review(s) available for arginine and arginine butyrate
Article | Year |
---|---|
Butyrate-induced reactivation of the fetal globin genes: a molecular treatment for the beta-hemoglobinopathies.
Topics: Amides; Animals; Arginine; Butyrates; Fetal Hemoglobin; Genes; Globins; Hemoglobinopathies; Humans | 1993 |
Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.
Topics: Antineoplastic Agents; Antiviral Agents; Arginine; Butyrates; Drug Therapy, Combination; Epstein-Barr Virus Infections; Ganciclovir; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Viral; Herpesvirus 4, Human; Humans; Lung Neoplasms; Lung Transplantation; Lymphoproliferative Disorders; Postoperative Complications; Tumor Cells, Cultured; Virus Latency | 2001 |
Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies.
Topics: Antineoplastic Agents; Antiviral Agents; Arginine; Butyrates; Clinical Trials as Topic; Combined Modality Therapy; Enzyme Induction; Epstein-Barr Virus Infections; Ganciclovir; Gene Expression Regulation, Neoplastic; Herpesvirus 4, Human; Humans; Lymphoma, Non-Hodgkin; Prognosis; Thymidine Kinase | 2001 |
Treatment advances in posttransplant lymphoproliferative disease.
Topics: Adoptive Transfer; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Arginine; Butyrates; Epstein-Barr Virus Infections; Hematopoietic Stem Cell Transplantation; Herpesvirus 4, Human; Humans; Immunologic Factors; Lymphoproliferative Disorders; Rituximab; T-Lymphocytes, Cytotoxic | 2010 |
Interventions for treating leg ulcers in people with sickle cell disease.
Topics: Actihaemyl; Anemia, Sickle Cell; Anti-Bacterial Agents; Arginine; Bandages; Butyrates; Carnitine; Humans; Isoxsuprine; Leg Ulcer; Oligopeptides; Randomized Controlled Trials as Topic | 2012 |
Interventions for treating leg ulcers in people with sickle cell disease.
Topics: Actihaemyl; Anemia, Sickle Cell; Anti-Bacterial Agents; Arginine; Bandages; Butyrates; Carnitine; Humans; Isoxsuprine; Leg Ulcer; Oligopeptides; Randomized Controlled Trials as Topic | 2014 |
4 trial(s) available for arginine and arginine butyrate
Article | Year |
---|---|
A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Arginine; beta-Thalassemia; Butyrates; Child; Child, Preschool; Female; Fetal Hemoglobin; Globins; Humans; Infusions, Intravenous; Male; RNA, Messenger | 1993 |
Butyrate increases the efficiency of translation of gamma-globin mRNA.
Topics: Adult; Anemia, Sickle Cell; Arginine; Butyrates; Fetal Hemoglobin; Globins; Humans; Peptide Chain Initiation, Translational; Protein Biosynthesis; Reticulocytes; RNA, Messenger | 2005 |
A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arginine; Butyrates; Child; Child, Preschool; Drug Therapy, Combination; Epstein-Barr Virus Infections; Female; Ganciclovir; Humans; Lymphoma; Male; Middle Aged | 2007 |
A randomized phase II trial of Arginine Butyrate with standard local therapy in refractory sickle cell leg ulcers.
Topics: Adult; Anemia, Sickle Cell; Arginine; Butyrates; Chronic Disease; Female; Humans; Leg Ulcer; Male; Middle Aged; Prospective Studies; Treatment Outcome; Wound Healing; Young Adult | 2010 |
34 other study(ies) available for arginine and arginine butyrate
Article | Year |
---|---|
[Protective activity of monoacetone glucose 3-butyrate, prodrug of n-butyric acid, against the fatal effect of encephalomyocarditis virus in mice].
Topics: Animals; Antineoplastic Agents; Arginine; Butyrates; Butyric Acid; Encephalomyocarditis virus; Glucose; In Vitro Techniques; Lethal Dose 50; Male; Mice; Prodrugs | 1992 |
Pharmacokinetic studies of N-butyric acid mono- and polyesters derived from monosaccharides.
Topics: Animals; Arginine; Butyrates; Galactose; Glucose; Monosaccharides; Polyesters; Rabbits | 1992 |
Butyric monosaccharide ester-induced cell differentiation and anti-tumor activity in mice. Importance of their prolonged biological effect for clinical applications in cancer therapy.
Topics: Animals; Antineoplastic Agents; Arginine; Butyrates; Cell Cycle; Cell Differentiation; Dose-Response Relationship, Drug; Glucose; Mice; Mice, Nude; Neoplasms, Experimental; Prodrugs; Structure-Activity Relationship; Tumor Cells, Cultured | 1991 |
Importance of coordinated immune stimulation in experimental antitumor treatment.
Topics: Adjuvants, Immunologic; Animals; Arginine; Butyrates; Drug Administration Schedule; Interferons; Male; Mice; Neoplasms, Experimental | 1985 |
Pharmacokinetic study of butyric acid administered in vivo as sodium and arginine butyrate salts.
Topics: Adult; Animals; Arginine; Blood Glucose; Butyrates; Butyric Acid; Half-Life; Humans; Insulin; Kinetics; Male; Mice; Rabbits; Tissue Distribution; Urea | 1989 |
Factors involved in interferon-induced or cholera toxin-induced steroidogenesis in Y-1 mouse adrenal tumour cells.
Topics: Adrenal Gland Neoplasms; Animals; Arginine; Bucladesine; Butyrates; Cell Line; Cholera Toxin; Colchicine; Cytochalasin B; Cytoskeleton; Interferon Type I; Ketosteroids; Mice | 1985 |
Effects of arginine butyrate on bacterial growth.
Topics: Arginine; Butyrates; Cell Division; Microbial Sensitivity Tests | 1986 |
Effect of arginine-butyrate on interferon induction by adenovirus.
Topics: Adenoviruses, Human; Animals; Arginine; Butyrates; Cells, Cultured; Chick Embryo; Fibroblasts; Interferon Inducers; Interferon Type I; Kinetics; Protein Biosynthesis | 1985 |
Antitumor therapy based on the use of an immune modulator, arginine butyrate and interferon.
Topics: Amniotic Fluid; Animals; Arginine; Butyrates; Cytoskeleton; Extracellular Matrix; Female; Humans; Immune System; Interferons; Mice; Mice, Inbred AKR; Neoplasms; Pregnancy; Propionibacterium acnes; Rats; Sarcoma 180 | 1984 |
Antitumor effect of arginine butyrate in conjunction with Corynebacterium parvum and interferon.
Topics: Animals; Arginine; Butyrates; Carcinoma, Ehrlich Tumor; Immunotherapy; Interferons; Male; Mice; Propionibacterium acnes; Sarcoma 180 | 1982 |
Effect of coordinated therapeutic assays using C. parvum, interferon and arginine butyrate on spontaneous disease and survival of AKR mice.
Topics: Animals; Arginine; Butyrates; Female; Interferons; Killer Cells, Natural; Leukemia, Experimental; Lymphoma; Mice; Mice, Inbred AKR; Propionibacterium acnes | 1983 |
[Protective action of arginine (or lysine) butyrate against the lethal effect of encelphalomyocarditis virus on mice].
Topics: Animals; Arginine; Butyrates; Dose-Response Relationship, Drug; Encephalomyocarditis virus; Enterovirus Infections; Lysine; Mice; Structure-Activity Relationship | 1981 |
[Inhibitory effect of arginine butyrate on the development of Crocker 180/TG tumor in Swiss mice].
Topics: Animals; Antineoplastic Agents; Arginine; Bacterial Vaccines; Butyrates; Male; Mice; Propionibacterium acnes; Sarcoma 180 | 1981 |
Butyrate derivatives. New agents for stimulating fetal globin production in the beta-globin disorders.
Topics: Adolescent; Adult; Amides; Anemia, Sickle Cell; Animals; Arginine; beta-Thalassemia; Butyrates; Child; Child, Preschool; Fetal Hemoglobin; Globins; Humans; Promoter Regions, Genetic | 1994 |
Increased fetal hemoglobin production in patients receiving valproic acid for epilepsy.
Topics: Adult; Amides; Arginine; Butyrates; Epilepsy; Fetal Hemoglobin; Humans; Phenylacetates; Phenylbutyrates; Reference Values; Valproic Acid | 1994 |
Reversing ontogeny.
Topics: Anemia, Sickle Cell; Arginine; beta-Thalassemia; Butyrates; Fetal Hemoglobin; Globins; Humans; Hydroxyurea | 1993 |
Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Arginine; beta-Thalassemia; Biomarkers; Butyrates; Child; Child, Preschool; Female; Hemoglobins; Humans; Infusions, Intravenous; Male | 1995 |
Present status of hemoglobinopathies in India.
Topics: Administration, Oral; Arginine; beta-Thalassemia; Butyrates; Chelating Agents; Chelation Therapy; Genetic Therapy; Humans; India | 1994 |
Rapid healing of chronic leg ulcers during arginine butyrate therapy in patients with sickle cell disease and thalassemia.
Topics: Adult; Anemia, Sickle Cell; Arginine; Butyrates; Female; Hemoglobins, Abnormal; Humans; Leg Ulcer; Thalassemia | 1994 |
Effect of DNA conformation on cisplatin adduct formation.
Topics: Antineoplastic Agents; Arginine; Butyrates; Chromatin; Cisplatin; DNA; DNA Adducts; Humans; Nucleic Acid Conformation; Tumor Cells, Cultured | 1996 |
Immunostimulating properties of the complexes of inosine derivatives.
Topics: Adjuvants, Immunologic; Adrenergic beta-Agonists; Animals; Arginine; Butyrates; Erythrocytes; Female; Hemolytic Plaque Technique; Immunoglobulin Fc Fragments; Inosine; Isoproterenol; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Phagocytosis; Rats; Sheep | 1995 |
Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Apoptosis; Arginine; Aspergillosis; Butyrates; Cyclophosphamide; Doxorubicin; Drug Synergism; Enzyme Induction; Epstein-Barr Virus Infections; Fatal Outcome; Ganciclovir; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Viral; Herpesvirus 4, Human; Humans; Lung Neoplasms; Lung Transplantation; Necrosis; Postoperative Complications; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Thymidine Kinase; Tumor Cells, Cultured; Vincristine; Viral Nonstructural Proteins | 1998 |
Arginine butyrate downregulates p210 bcr-abl expression and induces apoptosis in chronic myelogenous leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Arginine; Butyrates; Down-Regulation; Fusion Proteins, bcr-abl; Humans; Janus Kinase 1; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein-Tyrosine Kinases; Tumor Cells, Cultured | 1998 |
Leg ulceration in the sickle cell patient.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Arginine; Bandages, Hydrocolloid; Butyrates; Colloids; Combined Modality Therapy; Cost-Benefit Analysis; Erythropoietin; Female; Hospital Costs; Humans; Leg Ulcer; Length of Stay; Male; Occlusive Dressings; Recombinant Proteins; Recurrence; Retrospective Studies; Wound Healing | 1998 |
Hypoxia increases thrombospondin-1 transcript and protein in cultured endothelial cells.
Topics: Animals; Arginine; Butyrates; Cattle; Cells, Cultured; Cobalt; Cycloheximide; Dactinomycin; Endothelium, Vascular; Gene Expression Regulation; Humans; Hydroxamic Acids; Hypoxia; NG-Nitroarginine Methyl Ester; Oxygen; RNA, Messenger; Thrombospondin 1 | 1998 |
Bibliography. Current World Literature. Cancer in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antineoplastic Agents; Antiviral Agents; Arginine; Butyrates; Epstein-Barr Virus Infections; Ganciclovir; Humans; Incidence; Lymphoma, AIDS-Related; Matrix Metalloproteinases; Sarcoma, Kaposi | 2001 |
Arginine butyrate increases the cytotoxicity of DAB(389)IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rbeta gene.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arginine; Butyrates; Cell Survival; Cyclic AMP; Diphtheria Toxin; Dose-Response Relationship, Drug; Drug Synergism; Humans; Interleukin-2; Interleukin-2 Receptor beta Subunit; Leukemia; Lymphoma; Receptors, Interleukin; Receptors, Interleukin-2; Recombinant Fusion Proteins; Response Elements; Second Messenger Systems; Up-Regulation | 2002 |
Biochemical effect of intravenous arginine butyrate in X-linked adrenoleukodystrophy.
Topics: Adrenoleukodystrophy; Arginine; Butyrates; Child; Coenzyme A Ligases; Female; Humans; Infusions, Intravenous; Repressor Proteins; Saccharomyces cerevisiae Proteins | 2003 |
Fas ligand-mediated lethal hepatitis after rapid lysis of a localized natural killer cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arginine; Butyrates; Chemical and Drug Induced Liver Injury; Disease Progression; Fas Ligand Protein; Fatal Outcome; Female; Ganciclovir; Humans; Killer Cells, Natural; Lymphoma; Membrane Glycoproteins; Middle Aged; Severity of Illness Index; Tumor Necrosis Factors | 2006 |
Functional and molecular effects of arginine butyrate and prednisone on muscle and heart in the mdx mouse model of Duchenne Muscular Dystrophy.
Topics: Animals; Arginine; Behavior, Animal; Butyrates; Disease Models, Animal; Drug Therapy, Combination; Female; Gene Expression Profiling; Gene Expression Regulation; Heart; Mice; Mice, Inbred mdx; Muscles; Muscular Dystrophy, Duchenne; Prednisone; RNA, Messenger; Time Factors; Utrophin | 2010 |
Upregulation of brain utrophin does not rescue behavioral alterations in dystrophin-deficient mice.
Topics: Animals; Arginine; Brain; Butyrates; Dystrophin; Mice; Mice, Inbred mdx; Mice, Knockout; Muscular Dystrophy, Animal; Muscular Dystrophy, Duchenne; RNA, Messenger; Up-Regulation; Utrophin | 2012 |
Arginine butyrate: a therapeutic candidate for Duchenne muscular dystrophy.
Topics: Animals; Animals, Newborn; Arginine; Butyrates; Cells, Cultured; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Inbred mdx; Muscle Fibers, Skeletal; Muscular Dystrophy, Animal; Muscular Dystrophy, Duchenne; Up-Regulation; Utrophin | 2013 |
Low doses of arginine butyrate derivatives improve dystrophic phenotype and restore membrane integrity in DMD models.
Topics: Animals; Arginine; Butyrates; Cell Membrane Permeability; Cells, Cultured; Disease Models, Animal; Histone Deacetylase Inhibitors; Humans; Male; Mice; Mice, Inbred mdx; Muscle Fibers, Skeletal; Muscle Strength; Muscles; Muscular Dystrophy, Animal; Muscular Dystrophy, Duchenne; Utrophin | 2014 |
Arginine butyrate per os protects mdx mice against cardiomyopathy, kyphosis and changes in axonal excitability.
Topics: Action Potentials; Animals; Antineoplastic Agents; Arginine; Axons; Butyrates; Cardiomyopathies; Disease Models, Animal; Dystrophin; Electrocardiography; Kyphosis; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Muscle Strength; Muscle, Skeletal; Muscular Dystrophies; Severity of Illness Index; Time Factors; Tomography, X-Ray Computed; Ureohydrolases | 2014 |